| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Biomarin Pharmaceutical Inc. (BMRN) has 13 insiders with recent SEC Form 4 filings, including 0 buys and 12 sells. BMRN is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 159.4K | $9.05M | - | |
| VP | 80.0K | $4.54M | - | |
| VP | 55.1K | $3.13M | - | |
| Dir | 49.4K | $2.80M | - | |
| Dir | 46.4K | $2.64M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Mar 5, 2018 | Davis George Eric64 | EVP, General Counsel | Sell | 2,105 | $79.04 | $166,379.20 | -2.3% | |
| Feb 15, 2018 | Bienaime Jean Jacques68 | Chief Executive Officer | Sale+OE | 10,000 | $84.63 | $846,285.00 | -4.2% | |
| Feb 1, 2018 | Davis George Eric64 | EVP, General Counsel | Sale+OE | 30,000 | $90.66 | $2,719,665.00 | -26.6% | |
| Jan 5, 2018 | Bienaime Jean Jacques68 | Chief Executive Officer | Sale+OE | 10,000 | $90.32 | $903,203.00 | -4.2% | |
| Jan 2, 2018 | Lawlis V Bryan53 | Director | Sale+OE | 3,750 | $88.84 | $333,150.00 | -20.2% | |
| Jan 2, 2018 | Fuchs Henry J | President, Worldwide R&D | Sale+OE | 15,000 | $89.23 | $1,338,400.50 | -10.1% | |
| Dec 29, 2017 | Bienaime Jean Jacques68 | Chief Executive Officer | Sale+OE | 20,000 | $89.75 | $1,795,037.00 | -4.2% | |
| Dec 14, 2017 | Heron Elaine J | Director | Sell | 800 | $88.90 | $71,116.00 | -2.0% | |
| Nov 30, 2017 | Davis George Eric64 | EVP, General Counsel | Sell | 1,200 | $85.64 | $102,766.80 | -1.4% | |
| Sep 28, 2017 | Baffi Robert | EVP, Technical Operations | Sell | 18,415 | $92.43 | $1,702,030.50 | -10.4% |